Clarinex Approved - October 2007

The US Food and Drug Social control (FDA) approved Cymbalta (duloxetine hydrochloride) capsules for the brass of the pain associated with diabetic peripheral neuropathy.
This selective serotonin and norepinephrine reuptake inhibitor is the commencement drug specifically approved for this naming.
This month’s editorial reviews FDA new chemical approvals and labeling changes for:
Antidepressants
Cymbalta (duloxetine) Capsules
Antihistamines
Clarinex (desloratadine) Syrup
Development Hormones
Saizen (somatropin [rDNA origin]) for Subcutaneous Medical care
Opioid Analgesics
Palladone (hydromorphone hydrochloride extended-release) Capsules Surgical incision 1 of 5 Jane S.
Ricciuti, RPh, MS , Executive director Editor in chief, AdComm Bulletin , and Program Decision maker, U.S.
Regulatory Affairs/IDRAC, Liquent, Inc., Frederick, Old Line State.
This is a part of article Clarinex Approved - October 2007 Taken from "Generic Clarinex (Desloratadine) Page" Information Blog